GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » ROC (Joel Greenblatt) %

Innovative Pharmaceutical Biotech (HKSE:00399) ROC (Joel Greenblatt) % : 114,811.34% (As of Sep. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Innovative Pharmaceutical Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 114,811.34%.

The historical rank and industry rank for Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:00399' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -100558.75   Med: -907.74   Max: 30998.47
Current: 30998.47

During the past 13 years, Innovative Pharmaceutical Biotech's highest ROC (Joel Greenblatt) % was 30998.47%. The lowest was -100558.75%. And the median was -907.74%.

HKSE:00399's ROC (Joel Greenblatt) % is ranked better than
99.95% of 1887 companies
in the Consumer Packaged Goods industry
Industry Median: 11.43 vs HKSE:00399: 30998.47

Innovative Pharmaceutical Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Innovative Pharmaceutical Biotech ROC (Joel Greenblatt) % Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech ROC (Joel Greenblatt) % Chart

Innovative Pharmaceutical Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -100,558.75 -4,233.68 -907.74 11,296.51 -1,100.29

Innovative Pharmaceutical Biotech Semi-Annual Data
Dec13 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76,417.17 -1,331.38 -651.92 -1,847.91 114,811.34

Competitive Comparison of Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) %

For the Household & Personal Products subindustry, Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) % Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) % falls into.



Innovative Pharmaceutical Biotech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.167 + 0 + 0) - (49.785 + 0 + 2.972)
=-46.59

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.592 + 0 + 0) - (49.283 + 0 + 4.061)
=-47.752

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Innovative Pharmaceutical Biotech for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=648.11/( ( (0.941 + max(-46.59, 0)) + (0.188 + max(-47.752, 0)) )/ 2 )
=648.11/( ( 0.941 + 0.188 )/ 2 )
=648.11/0.5645
=114,811.34 %

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovative Pharmaceutical Biotech  (HKSE:00399) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Innovative Pharmaceutical Biotech ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Traded in Other Exchanges
N/A
Address
168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG
Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.
Executives
Mao Yumin 2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Chau Yiu Ting 2101 Beneficial owner
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines